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Diabetes is a condition of multifactorial origin, involving several molecular mechanisms related to the intestinal
microbiota for its development. In type 2 diabetes, receptor activation and recognition by microorganisms from
the intestinal lumen may trigger inflammatory responses, inducing the phosphorylation of serine residues in insulin
receptor substrate-1, reducing insulin sensitivity. In type 1 diabetes, the lowered expression of adhesion proteins
within the intestinal epithelium favours a greater immune response that may result in destruction of pancreatic
β cells by CD8+ T-lymphocytes, and increased expression of interleukin-17, related to autoimmunity. Research in
animal models and humans has hypothesized whether the administration of probiotics may improve the prognosis
of diabetes through modulation of gut microbiota. We have shown in this review that a large body of evidence
suggests probiotics reduce the inflammatory response and oxidative stress, as well as increase the expression of
adhesion proteins within the intestinal epithelium, reducing intestinal permeability. Such effects increase insulin
sensitivity and reduce autoimmune response. However, further investigations are required to clarify whether the
administration of probiotics can be efficiently used for the prevention and management of diabetes.
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According to the World Health Organization [1], the
global prevalence of diabetes is approximately 10%,
reaching up to 33% of the population in some regions.
Diabetes is a condition of multifactorial origin, including
genetic and environmental factors, and accounts for 3.5%
of the mortality cases due to non-communicable chronic
diseases. Scientific evidence suggests increased inflamma-
tory stress is related to molecular mechanisms leading to
insulin resistance, and the intestinal microbiota interacts
with environmental factors and susceptible genetic factors,
contributing to the development of diabetes [2].
The human gastrointestinal tract contains in average 1014
microorganisms/ml of luminal content, and features
over 5000 bacterial species. Among bacterial species,
approximately 90% of them belong to the Bacteroi-
detes phyla, composed mainly of Gram– bacteria, and
the Firmicutes phyla, composed mainly of Gram+ bacteria.
It has been suggested that the intestinal microbiota
composition is associated with conditions such as aller-
gies, intestinal inflammatory diseases, cancer, diabetes,* Correspondence: jfemota@gmail.com
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unless otherwise stated.cardiovascular diseases and dyslipidaemia [3,4]. It has
also been suggested that altered intestinal microbiota
leads to increased intestinal permeability and mucosal
immune response, contributing to the development of
diabetes. Increased intestinal permeability is a result of
reduced expression of tight junction proteins, eventually
favouring the translocation of bacterial lipopolysaccharide
(LPS), which may result in metabolic endotoxemia and
insulin resistance [5,6].
Modulation of intestinal microbiota by probiotics may
facilitate the management of a number of clinical condi-
tions [7]. Probiotics may be involved in the maintenance
of a healthier gut microbiota, and have also been identified
as effective adjuvants in insulin resistance therapies [8-10].
Hence, this systematic review appraises the current litera-
ture covering gut microbiota, probiotics and diabetes.
Our aim is to clarify the currently described effects of
probiotics in the prevention and management of type 1
(T1D) and type 2 (T2D) diabetes mellitus.Methods
A systematic literature review has been performed over
the electronic databases Medline PubMed and SciELO
(The Scientific Electronic Library Online). The reference
list of identified articles has also been reviewed. For thisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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betes," "oxidative stress", "probiotics", "inflammation",
"insulin" and "microbiota". The logical connectives "and",
"or" and "and not" were systematically used to combine
descriptors and terms used to trace the publications.
As a result of this appraisal conducted in December
2013, 287 publications were identified. Subsequently,
the articles that met the following inclusion criteria
were selected: (a) experimental studies that investigated
assessment of insulin sensitivity, glucose tolerance test,
intestinal permeability and or markers of oxidative stress
and inflammation; (b) literature review articles; (c) articles
preferably published after 2002.
After reconsideration based on the inclusion criteria,
166 articles were excluded for one of the two following
reasons: the effects of probiotics were related to other
pathologies other than diabetes; or, probiotics were not
the main objective of the study. Therefore, 121 articles
met all the inclusion criteria and were reviewed.
Intestinal microbiota and type 2 diabetes
Muscle and adipose tissue resistance to insulin actions
observed in T2D is triggered mainly by a complex com-
bination of genetic predisposition, body composition,
nutritional and environmental factors. Insulin receptor,
glucose transporter and post-receptor perturbations are
observed in T2D. Eventually, peripheral tissues exposed to
chronic compensatory hyperinsulinemia become resistant
to insulin [11]. Studies have shown the intestinal micro-
biota is associated with the development of metabolic
diseases, as obese and diabetic subjects present pertur-
bations in the proportions of Firmicutes, Bacteroidetes
and Proteobacterias [4,12].
Mammals present sterile gastrointestinal tract at birth,
and their microbiota is gradually accumulated after birth
through the physical contact with the breast and the
environment [13]. Infants’ intestinal microbiota is mainly
formed by Bifidobacteria and Enterobacteria, and it changes
progressively into a more complex pattern, observed in
adults [14]. These microorganisms and their metabolites
interact with the intestinal epithelial cells differently in
the small and large intestines. Such microbiological and
biochemical variations are attributed to the distinct
anatomical features of these two organs, and also to the
mucus produced by goblet cells. Mucus acts as bacterial
insulator at intestinal barrier level, but does not fully
impede bacterial fragments to diffuse through the intes-
tinal barrier, binding to pattern recognition receptors
(PRR). Such phenomenon contributes not only to the
maintenance of the intestinal barrier but also to the
innate and adaptive immune responses [15].
Diet is pivotal for regulation of the intestinal microbiota,
excess of nutrients like saturated [16] and polyunsaturated
fatty acids [17] or shortage of oligosaccharides [18,19] andphytochemicals [20] can modify the bacterial metabolic
activity [21]. High fat diets modify the intestinal micro-
biota, leading to increased intestinal permeability and
susceptibility to microbial antigens, which ultimately
correlates with the occurrence of metabolic endotoxemia
and insulin resistance [22].
The molecular mechanisms involved in high fat diets
and modulation of the intestinal microbiota are not fully
elucidated, but as this typical diet increases fatty acid
oxidation in the liver and adipose tissue, the evidence
available suggests the reactive oxygen species (ROS)
generated reduce mucus production in the intestinal
epithelium. Thus, the weakened intestinal barrier integ-
rity allows the translocation of intestinal bacteria [23].
Furthermore, production of malondialdehyde as result
of polyunsaturated fatty acid oxidation induces damage
to the epithelial cell membranes, increasing intestinal
tight junction permeability [24,25].
Diabetic individuals have lower counts of Bifidobacterium
and Faecalibacterium prausnitzii, both of them Gram+ [26]
with anti-inflammatory properties [26,27]. Despite the
perturbations already observed in the intestinal microbiota
of type 2 diabetic subjects, it is still necessary to elucidate
whether the variations in the microbiota, intestinal barrier
and metabolic endotoxemia are causes or consequences of
diabetes. Interestingly, Mehta et al. [28] showed that acute
inflammation induced by intravenous administration
of LPS promotes metabolic endotoxemia and systemic
insulin resistance, following modulation of specific
adipose inflammatory and insulin signaling pathways.
The relationship between LPS and the development of
T2D has been observed in some clinical trials [29-33].
Concurrent with metabolic endotoxemia, translocation
of live bacteria from the intestinal barrier into the blood
appears to be related to the development of T2D [34,35].
One of the features common to metabolic diseases
such as obesity and T2D is a mild chronic inflammatory
state, which could possibly be – among other factors – the
result of TLR activation by LPS, present in the cell wall
of Gram– bacteria. The TLRs comprise a large family
of cell membrane proteins present in different types of
cells, recognizing microbe-associated molecular patterns
(MAMPs) during the inflammatory response. TLRs
play an important role in the innate immune system
due to their ability to detect the presence and nature
of pathogens, providing the first line of host defence.
However, TLRs also stimulate adaptive immunity, once
they induce the secretion of inflammatory cytokines
[36]. These receptors feature leucine-rich repeat (LRR)
extracellular domains, and Toll/interleukin-1 receptor
(TIR) intracellular domains [37].
Toll-like receptors 4 (TLR4) are present in tissues
targeted for insulin actions. Such actions may become
compromised upon TLR4 stimulation, through activation
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centration of reactive oxygen species (ROS) [38,39].
Reduced Bifidobacterium due to a high-fat diet intake
has been associated with higher concentrations of LPS,
one of the features of metabolic endotoxemia [40]. A
high-fat diet intake promotes the death of Gram– bac-
teria, contributing to LPS production in the gut and its
translocation into intestinal capillaries and the general
circulation [41]. Such effect leads to higher concentrations
of pro-inflammatory cytokines in various tissues via TLR4
activation [42,5,43].
Inflammation levels are pivotal for intestinal microbiota
regulation and for the development of insulin resistance.
The inflammatory response is activated by MAMPs
such as LPS, flagellin, peptidoglycans, damage-associated
molecular pattern molecules (DAMPS), high-mobility
group protein (HMGB), DNA and nucleotides [36]. The
recognition of DAMPS and MAMPs is mediated by
specific receptors, including toll-like receptors (TLRs),
C-type lectin receptors (CLRs), receptors for advanced
glycation end products (RAGE), nucleotide binding
oligomerization domain-like receptor (NLR) intracellular
domains, and retinoic acid inducible gene type 1 (RIG-1).
Activation of such receptors results in phosphorylation
of c-Jun N-terminal kinases (JNKs) and IkappaB kinase
complexes (IKKβ), consequently amplifying the inflam-
matory response [37].
As TLR4 forms a molecular complex with its soluble
myeloid differentiation factor-2 (MD2) co-receptor at
cell surface level, it becomes a binding site for LPS. The
now formed complex TLR4-MD2-LPS triggers a cascade of
inflammatory events, leading to the activation of nuclear
factor kappa B (NFκB) via activation of the intracellular
Toll-interleukin 1 receptor domain-containing adapter
protein (TIRAP), and of the TIR domain-containing
adaptor-inducing interferon-β [TRIF]-related adaptor
molecule (TRAM). TIRAP and TRAM activation triggers
the myeloid differentiation factor 88 (MyD88) and the
TRIF pathways, respectively. The MyD88 recruits proteins
of the families Interleukin-1 receptor-associated kinase
(IRAK) and TNF-α receptor-associated factor 6 (TRAF6).
TRAF6 is responsible for activation of the transforming
growth factor β-activated kinase 1 (TAK1); activated
TAK1 promotes phosphorylation of the kappa beta
kinase (IKK) inhibitors α, β and γ [44].
Phosphorylated IKK complexes degrade the inhibitory
kappa B (IkB), translocating the NFκB to the nucleus,
subsequently inducing the expression of pro-inflammatory
cytokines. Activation of inflammatory pathways induced
by LPS-TLR4 increases the expression of inducible nitric
oxide synthase [45], promoting the S-nitrosation/S-
nitrosylation phenomenon. The generated nitric oxide
reacts with cysteine residues to form adducts of S-
nitrosothiols [46], inhibiting the insulin transductionsignal via phosphorylation of insulin receptor 1 substrate
(IRS-1) in serine, which in turn leads to insulin resistance
in hepatic, muscle and adipose tissues [47,48]. Others
studies have shown pro-inflammatory cytokines induce
phosphorylation of IRS-1 in serine [49,50], whose activation
may mediate the inhibition of insulin receptor tyrosine kin-
ase and protein kinase B (AKT) signalling, also increasing
the degradation of IRS-1 [51,52].
Intestinal microbiota and type 1 diabetes
Type 1 diabetes results from autoimmune destruction of
pancreatic β cells in genetically predisposed individuals
[53]. β cell destruction involves innate and adaptive
immune responses, and when around 80% of the β cells
are affected, the first signs of diabetes become manifested
[54]. At this point insulin therapy is mandatory.
Some epidemiological evidence – such as declined
incidence of T1D in Caucasian Europeans, increased
incidence in children under five in some demographic
areas such as North America, Australia and North Africa,
as well as T1D discordance in monozygotic twins –
suggests the contribution of environmental factors for
the development of this condition [55,56].
The intestinal mucosa is a major site for pathogen
invasion: when undamaged, it provides the first line of
defence against antigens. The intestinal wall is constituted
of a layer of mucus, IgA-secreting cells, antimicrobial
peptides, and a complex system of epithelial barrier
formed by adhesion and tight junctions [57]. The intes-
tinal microbiota is capable of modulating the immune
response and consequently autoimmunity; the influence
of intestinal bacteria in the pathogenesis of T1D has
been demonstrated [58].
The mechanisms associating gut microbiota and T1D
development are yet to be fully understood. Studies in
humans tend to suggest this possibility; however, these
results have not yet proven a direct relationship between
changes in intestinal microbiota and the development of
autoimmune diseases.
Increased intestinal permeability may facilitate the
absorption of antigens which can injure pancreatic β
cells [59]. Individuals susceptible to T1D and other
autoimmune diseases present inadequately functioning
intestinal barrier [60], allowing greater exposure of anti-
gens to the immune system. However, the mechanisms
resulting in this condition – leaky gut – before T1D has
developed itself have not yet been fully understood. T1D
patients show perturbations in the structure of tight junc-
tions as result of decreased zonulin expression, a protein
related to the regulation of intestinal permeability [61],
as well as increased paracellular space between intestinal
epithelial cells [6].
Antigens of dietary or pathogenic origins, facilitated by
increased intestinal permeability, trigger inflammation
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of pancreatic β cells [62-64]. Bovine insulin for example,
which can be found in cow’s milk, appears to sensitize
intestinal T lymphocytes in susceptible children, which in
turn could participate in the autoimmune destruction of
pancreatic β cells [65]. Furthermore, changes in intestinal
microbiota may result in altered inflammatory responses,
an important event in the pathogenesis of autoimmune
diseases such as T1D [66]. Children with T1D showed
higher counts of Clostridium, Bacteroides and Veillonella,
followed by lower counts of Bifidobacterium and Lactoba-
cillus, than healthy children [67]. Another study reported
in T1D increased counts of Bacteroides ovatus and de-
creased Bacteroides fragilis [68].
Intestinal pathophysiology is related to the development
of T1D, once increased intestinal permeability is detect-
able even before the clinical onset of the disease [69]. A
pioneering study by Brugman and colleagues [70] found
in BioBreeding diabetes-prone (BB) rats that progressed
into T1D presented reduced variety of bacteria of the
phylum Bacteroidetes, as compared to control rats.
Ribosomal RNA analyses of stool samples of BB and
BioBreeding diabetes-resistant (BBR) rats showed increased
presence of bacteroidetes and clostridium in BB rats, and
increased presence of lactobacilli and bifidobacterium
in BBR rats [71]. The alterations observed in BB rats
may be due to limited functioning of their immune system
[72]; however, this causal relationship remains under
investigation.
In agreement with these results, a study [73] found that
healthy children have more diverse and stable intestinal
microbiota as compared to children who developed T1D.
In another study, the gut microbiota composition of T1D
children showed increased virulence factors, phage, pro-
phage, motility genes and higher response to stress [74].
Corroborating these findings, it has also been found in
T1D children lower counts of bacteria producing butyrate,
a short chain fatty acid with anti-inflammatory actions
[75]. Butyrate reduces bacterial translocation, improves
the organization of tight junctions [76] and stimulates the
synthesis of mucin, a glycoprotein maintaining the integ-
rity of the intestinal epithelium [77].
MyD88 knockout mice were protected from developing
T1D, and showed lower expression of TNF-α in the
pancreatic lymph nodes as compared to wild-type mice
[78]. The same study found that MyD88 deletion was
associated with lower ratios of Firmicutes over Bacteroi-
detes, and increased counts of Lactobacilli, Rikenellaceae
and Porphyromonadaceae. Another experimental study
showed that antibiotic administration prevented insulitis
and pancreatic β cell destruction in mice with virus-
induced T1D through mechanisms involving reduction
of the innate immune response in pancreatic lymph
nodes and Peyer's patches [79]. These results supportthe hypothesis that the innate immune system is related
to the development of T1D.
In contrast, intestinal microbiota destruction of MyD88
knockout rats by broad-spectrum antibiotics was associated
with increased incidence of T1D, as compared to germ-free
mice [78]. This result suggests that specific components
of the intestinal microbiota may prevent the activation
of autoimmune T cells independently of the presence of
MyD88 in ways not yet fully understood.
Studies in T1D animal models have elucidated several
pathogenic pathways that may lead to immune-mediated
destruction of β cells. CD8+ cells, for example, can destroy
β cells via perforin expression. The presence of proin-
fammatory cytokines induces damage to β cells, and
molecules of the TNF family induce apoptosis [80].
Studies in humans have also shown involvement of the
immune system in the destruction of pancreatic β cells.
Interferons produced in inflammatory and infectious
responses accelerate the destruction of pancreatic β
cells by inducing the expression of MHC class I [81].
Higher expression of MHC class I epitopes [82] and CD8+
T cells [83] have been observed in the pancreas of T1D in-
dividuals. CD4+ and CD8+ T cells are related to the
pathogenesis of T1D, once CD4+ may invade pancreatic
islets, and CD8+ may initiate β cell destruction [84].
Studies focusing on specific bacterial lineages have
revealed that Bacteroides fragilis, a member of the Bacter-
oidetes phyla [85], present the ability to reduce intestinal
inflammation, whilst segmented filamentous bacteria are
able to activate IL-17-producing CD4+ T helper cells
(TH17), which stimulate autoimmune responses and the
production of inflammatory cytokines [86-88]. Interest-
ingly, TH17 induction is dependent upon the individual’s
genetic background [86].
It has been proposed the maintenance of normal
microbiota – the 'old friends hypothesis’ – is promoted
by lower modulatory levels of regulatory T cells secreting
IL-10 and transforming growth factor beta (TGFβ), which
decrease inflammation [89]. Geuking et al. [86] proposes
this mutualistic response to be related to a variety of
regulatory T cell subsets in a complex real-life gut flora,
inclusive of symbiotic, commensal with the potential to
become pathogenic, and pathogenic microorganisms. In
that complex scenario, further research is needed to
specify which Bacteroidetes species reduce intestinal
inflammation and promote regulatory T cells induction.
Taken together however, these responses support the
maintenance of self-tolerance, and suggest an important
role of probiotics in maintaining a healthier intestinal
microbiota [64].
Evidences from experimental and clinical studies
Probiotics are a class of live microorganisms which,
when ingested in appropriate amounts, may confer health
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be associated with immune system stimulation, decreased
cholesterol blood levels, protection against respiratory and
intestinal diseases, reduction of inflammatory responses
and antitumorigenic effects. These alleged health claims
apparently stem from the ability of probiotics to secrete
antimicrobial substances, competing with other patho-
gens, strengthening the intestinal barrier and modulating
the immune system [91]. Bifidobacteria and lactobacilli
are the most commonly used strains in functional foods
and dietary supplements [92]. A summarized list of studies
evaluating the effects of probiotic administration in experi-
mental models and clinical investigations in diabetes melli-
tus is presented in Tables 1 and 2.
It has been shown that Lactobacillus acidophilus, L
fermentum, L gasseri and L rhamnosus modulate the
expression of genes encoding junction and adhesion
proteins E-cadherin and β-catenin, and reduce the expres-
sion of protein kinase C-δ (PKC-δ) [93]. PKC-δ activation
results in dispersion of adherence junctions, increasing
intestinal permeability [94]. On the other hand, β-catenin
phosphorylation induced by probiotics may strengthen
the complex E-cadherin/β-catenin, supporting the main-
tenance of adhesion junction from the binding site of
E-cadherin to the cytoskeleton [95].
The administration of 108 colony-forming units (CFU)
of Lactobacillus johnsonii N6.2 per day to rats increased
the number of Paneth cells [96]. Paneth cells are constitu-
ents of the intestinal barrier which produce antimicrobial
proteins, contributing to reduce intestinal permeability
[97]. Experimental studies have shown the administration
of Lactobacillus johnsonii to diabetes-prone rats may
reduce the incidence of diabetes by increasing the gene
expression of claudin-1 and decreasing oxidative stress
[98], and it may also modulate the TH17 response,
impairing the development of T1D in diabetes-prone mice
[99]. Several microbial species possess the ability to modu-
late the TH17 phenotype, particularly Gram+ bacteria
[100]. Even though TH17 induces pancreatic inflamma-
tion, progression to T1D will occur only after this cell
differentiates into TH1; so apparently the formation of
differentiated TH17 phenotypes appears to inhibit the
manifestation of the diabetogenic phenotype [101].
The consumption of dahi, a traditional Indian fermented
milk, containing L. acidophilus, L. casei and L. lactis has
been shown to reduce the glycemic curve and HbA1c
[102]. L. plantarum DSM15313 is also suggested to
reduce glycaemia, improve glucose tolerance and reduce
insulin resistance [103]. VSL#3, a commercially available
mixture of probiotics containing 3 × 1011 CFU/g of Bifido-
bacterium longum, B. infantis and B. breve, has been
shown to improve insulin signalling and reduce inflamma-
tion in the adipose tissue of ApoE−/− rats [104]. VSL#3
has been also shown to reduce the depletion of hepaticnatural killer cells and minimize the activation of NFkB in
wild-type male C57BL6 mice fed a high fat diet [105]. A
study investigating the effects of VSL#3 on the occurrence
of diabetes in non-obese diabetic mice showed this pro-
biotic mixture has impaired the development of T1D via
three major pathways: 1) supressing both inflammation
and pancreatic β cell death, 2) increasing the production
of IL-10 from Peyer’s patches, a component of the gut-
associated lymphoid tissue, and 3) increasing the IL-10
expression in the pancreas [106]. IL-10 is an anti-inflam-
matory cytokine which inhibits antigen presentation
and proinflammatory cytokine production [107], whereas
depletion of hepatic natural killer cells is linked to the
development of hepatic insulin resistance [108].
Consumption of dahi enriched with Lactobacillus acid-
ophilus NCDC14 and Lactobacillus casei NCDC19 has
apparently reduced lipid peroxidation, HbA1c and amelio-
rated intestinal transit in diabetic rats; however, without
concomitant blood glucose reduction [109]. Similar study
has shown preserved enzymatic activity of the antioxidant
enzymes glutathione peroxidase, superoxide dismutase
and catalase [110]. The administration of Lactobacillus
reuteri GMNL-263 has been shown to reduce glycaemia
and HbA1c levels, and to prevent renal fibrosis [111]. It
has also been suggested that Bifidobacterium adolescentis
improves insulin sensitivity [112] via increased production
of glucagon-like peptide 1 (GLP-1) [2]. GLP-1 enhances
glucose tolerance via complex mechanisms involving
modulation of insulin secretion, pancreatic cell mass and
food intake [113].
Administration of 109 CFU of Bifidobacterium animalis
ssp. lactis 420 to high fat diet-fed diabetic rats appears
to reduce the inflammatory cytokines TNF-α, IL-1β,
plasminogen activator inhibitor-1 (PAI-1) and IL-6 in
mesenteric adipose tissue, as well as to improved insulin
sensitivity [34]. In the same way, Lactobacillus rhamnosus
GG appears to reduce translocation of NFkB to the nu-
cleus, degradation of Ikβ, and activation of the TLR4 by
LPS [114].
Intestinal microbiota modulation by probiotics appears
to offer beneficial outcomes to insulin-resistant individuals
via mechanisms both related and unrelated to inflammation
[115]. However, the effectiveness of clinical trials employing
probiotics may be specific to the strain used and cannot be
extrapolated to other strains or species [116].
A study has shown daily consumption of 200 ml of a
shake containing 4 × 108 CFU/100 ml of Lactobacillus
acidophilus, 4 × 108 CFU/100 ml of Bifidobacterium bifi-
dum and 1 g/100 ml of fructooligosaccharides, resulted
in blood glucose reduction in T2D individuals [8]. It has
also been shown that T2D individuals, after consuming a
yogurt containing 7,23 × 106 CFU of L. acidophilus La5 and
6,04 × 106 CFU of B. lactis Bb12 for 6 weeks, presented re-
duced fasting glucose and reduced HbA1c levels, followed
Table 1 Effects of probiotic administration on diabetes mellitus – Experimental studies
References Probiotics Type of cell/animal model Quantity Study period Results
[34] Bifidobacterium animalis subsp. lactis 420 C57BL/6, ob/ob, CD14−/−,
ob/obxCD14−/−, Myd88−/−,
Nod1−/−or Nod2−/−mice
fed a high fat diet
109 CFU/day 6 weeks TNF-α, IL-1β, PAI-1 and IL-6
nsulin sensitivity
[94] L. acidophilus (PZ 1041), L. gasseri
(PZ 1160), L. fermentum (PZ 1162),
and L. rhamnosus (PZ 1121)
T84 cell - - acidophilus, L. fermentum, and L. gasseri:
two genes encoding adherence junction
roteins β-catenin and E-cadherin
Transepithelial electrical resistance
PKCδ
[96] Lactobacillus johnsonii N6.2 subsp.
infantis ATCC
Caco-2 cell/BB rats 1010 to 1011 CFU/L in cell culture
and 108 CFU/day in rats
- Paneth cell
[99] Lactobacillus johnsonii N6.2 and
Lactobacillus reuteri TD1
BB rats 108 CFU/day 141 days ctobacillus johnsonii N6.2: ↓ incidence of T1D;
goblet cells and claudin-1; ↓ hexanoyl-lysine
xidative stress biomarker)
[100] Lactobacillus johnsonii N6.2 and
Lactobacillus reuteri TD1
BB rats, NOD mice, and
C57BL/6 mice
1 × 108 CFU/day 140 days sitive TH17 phenotype modulation
[102] L. acidophilus, L. casei, and L. lactis Male Wistar rats fed a
high fructose diet
diet supplemented with
15% of dahi ad libitum
8 weeks Blood glucose, HbA1c, glucose intolerance,
lasma insulin, liver glycogen, plasma total
olesterol, triacylglycerol, low-density lipoprotein
olesterol, very low-density lipoprotein cholesterol,
d blood free fatty acids
[103] L. plantarum DSM 15313 Female C57BL/6 J mice
fed a high fat diet
25 × 108 CFU/day 20 weeks Blood glucose
[104] VSL#3 (L. acidophilus MB 443, L. delbrueckii
subsp. bulgaricus MB 453, L. casei MB 451,
L. plantarum MB 452, B. longum Y10,
B. infantis Y1, B. breve Y8, and S. salivarius
subsp. thermophilus MB 455)
ApoE−/−C57BL6 male mice 25 × 108 CFU/day 12 weeks Insulin
Glucose tolerance
Insulin signaling
NF-α and RANTES
IL-10
[105] VSL#3 (L. acidophilus MB 443, L. delbrueckii
subsp. bulgaricus MB 453, L. casei MB 451,
L. plantarum MB 452, B. longum Y10, B.
infantis Y1, B. breve Y8, and S. salivarius
subsp. thermophilus MB 455)
NOD mice 1.5 × 109 CFU/day 12 weeks Hepatic NKT cell depletion
IKKβ activity
NF-κB binding activity
nsulin signaling
[106] VSL#3 (L. acidophilus MB 443, L. delbrueckii
subsp. bulgaricus MB 453, L. casei MB 451,
L. plantarum MB 452, B. longum Y10, B.
infantis Y1, B. breve Y8, and S. salivarius
subsp. thermophilus MB 455)
Female NOD mice 9 mg/week 70 weeks Incidence of auto-immune diabetes
Insulitis and decreased rate of β-cell destruction
IL-10
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Table 1 Effects of probiotic administration on diabetes mellitus – Experimental studies (Continued)
[109] Lactococcus lactis ssp. diacetylactis NCDC 60,
L. acidophilus NCDC 14, and L. casei NCDC 19
Male Wistar diabetic rats 15 g/day (8,83 CFU/g lactobacilli
and 7,89 log CFU/g lactococci)
15 weeks ↑ Gastric emptying
Dahi probiotic feeding did not change blood
glucose levels
↓ Thiobarbituric acid-reactive species in
intestinal tissues
↓ HbA1c
[111] L. reuteri GMNL-263 Male Sprague–Dawley
diabetic rats
1 × 109 CFU/day 4 weeks ↓ HbA1c and blood glucose
↓ JAK2 and STAT1 phosphorylation
↓ PAI-1
[112] Bifidobacterium adolescentis Male Wistar rats fed a
high fat diet
- 12 weeks ↓ Body weight
↑Insulin sensitivity
[114] Lactobacillus rhamnosus GG HT-29 cells 107-109 CFU/mL - ↓ NF-kB nuclear translocation
↓ LPS-induced IκBα degradation
HbA1c: Glycated hemoglobin; NF-kB: nuclear factor kappa B; LPS: Lipopolysaccharides; IκBα: inhibitory kappa B alpha; TNF-α: tumor necrosis factor alpha; IL-1β: interleukin-1 beta; PAI-1: plasminogen activator inhibitor-1; IL-6:
interleukin-6; JAK2: Janus kinase 2; STAT1: signal transducer and activator of transcription 1; IL-10: interleukin-10; IKKβ: inhibitors of kappa beta kinase beta; NKT: natural killer T cells; RANTES: regulated upon activation, normal
T-cell expressed and secreted; Th17: T helper 17; T1D: type 1 diabetes.
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Table 2 Effects of probiotic administration on diabetes mellitus – clinical studies
References Probiotic Study design/subjects Sample Size Quantity Study period Results
[8] Lactobacillus acidophilus
and Bifidobacterium bifidum
Double-blinded, placebo-controlled,
randomized study, T2D females
aged 50–65 years
Placebo group: n = 10;
Probiotic group: n = 10
2 daily doses of 100 mL symbiotic
shake containing 4 × 108 CFU/100 mL
Lactobacillus acidophillus, 4 × 108
CFU/100 mL Bifidobacterium bifidum
45 days ↓ Glycemia
[9] Lactobacillus acidophilus
La5 and Bifidobacterium
lactis Bb12
Double-blinded, randomized
controlled clinical trial, T2D
patients aged 30–60 years
Placebo group: n = 32;
Probiotic group: n = 32
300 g/day of probiotic and conventional
yogurt day 1: 7,23 × 106 of L. acidophilus
La5 and 6.04 × 106 cfu/g of B. lactis Bb12
6 weeks ↓ Fasting blood
glucose and HbA1c
↑ Erythrocyte SOD
and GPx
↑ Total antioxidant
capacity
[10] L. acidophilus NCFM Double-blinded, placebo-controlled,
randomized study, T2D males
Placebo group: n = 24;
Probiotic group: n = 24
- 4 weeks Preserved insulin
sensitivity
No effect on systemic
inflammatory response
[117] Lactobacillus rhamnosus
GG (ATCC 53 103) and
Bifidobacterium lactis Bb12
Prospective, randomized study,
mother–baby pairs
Dietetic Intervention + probiotics:
n = 85; Dietetic Intervention + placebo:
n = 86; Control + placebo: n = 85
Lactobacillus rhamnosus GG: 1010
CFU/day; Bifidobacterium lactis
Bb12: 1010 CFU/day
33 months ↓ Risk of GDM
[118] Lactobacillus rhamnosus
GG, ATCC 53 103 and
Bifidobacterium lactis Bb12
Randomized, prospective, parallel-
group, combined dietary counselling,
pregnant women
Diet + probiotics: n = 85; Diet + placebo:
n = 86; Control + placebo: n = 85
Lactobacillus rhamnosus: 1010
CFU/day; Bifidobacterium lactis
Bb12: 1010 CFU/day
18 months ↓ Blood glucose
↓ Insulin
↓ Insulin sensitivity
[119] L. plantarum WCFS1 Double-blinded, randomized
crossover study, healthy subjects
n = 14 1012 CFU 6 hours ↓ Degradation of
transepithelial electrical
resistance
↑ ZO-1 in tight junctions
GDM: gestational diabetes mellitus; GPx: Glutathione peroxidase; HbA1c: Glycated hemoglobin; SOD: Superoxide dismutase; T2D: type II diabetes mellitus; ZO-1: zonula occludens-1.
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Figure 1 Schematic representation of probiotic actions in type 1 and type 2 diabetes. Probiotic consumption increases the number of
bifidobacteria, and increased expression of adhesion proteins reduces intestinal permeability, impairing the activation of TLR4 by LPS. As result,
NFkB activation pathways are blocked. The induction of TH17 cells is also inhibited, preventing pancreatic infiltration of CD8+ T cells.
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peroxidase, as compared to a control group [9].
The administration of capsules containing 1010 CFU of
L. acidophilus NCFM for 4 weeks has preserved insulin
sensitivity in a sample population of non-diabetic and dia-
betic individuals [10]. Pregnant women receiving intensive
nutritional counselling and a food supplement containing
1010 CFU of L. rhamnosus GG and 1010 CFU of B. lactis
Bb12 presented improved glucose tolerance and reduced
HbA1c levels in relation to a control group receiving only
a control, healthy diet [117]. A similar study from the
same research group observed that nutritional counselling
combined with probiotic supplementation reduced blood
glucose during pregnancy and up to 12 months after deliv-
ery, reduced insulin concentrations and improved insulin
sensitivity more effectively than nutritional counselling
alone [118].
A study has shown the consumption of 1012 CFU of
Lactobacillus plantarum WCFS1 improved the localization
of the scaffolding protein zonula occludens (ZO)-1 in areas
surrounding the tight junctions [119]. Accumulation of
these proteins is associated with increased protection at
intestinal barrier level [120], and the organization of
these occlusion proteins may occur via activation of
TLR2 receptors on the apical surface of the intestinal
epithelium [119].
Molecular mechanisms involving the anti-diabetic effects
of probiotics are not fully elucidated, but may be related to
reduction of oxidative stress, immunomodulation, attenu-
ation of inflammation and modification of the intestinal
microbiota (Figure 1) [9]. Furthermore, probiotics have
been shown to improve the absorption of antioxidants and
reduce post-prandial lipid concentrations, actions directly
related to oxidative stress [121].
Conclusions
The intestinal microbiota presents a vast set of antigens
which may participate in the modulation of immunological
diseases. An intestinal barrier presenting full integrity en-
sures specific interactions between the luminal antigens
and the host. Functional disarrangements may contribute
to the autoimmune destruction of pancreatic β cells, which
leads to T1D, and increased expression of inflammatory
cytokines may lead to insulin resistance and T2D.
The evidence available from experimental studies and
clinical trials supports our suggestion that the modulation
of the intestinal microbiota by probiotics may be effective
towards prevention and management of T1D and T2D.
The findings discussed here provide an insight into the
investigation of further hypotheses aiming to elucidate
molecular mechanisms involved in the modulation of
intestinal microbiota by probiotic administration, their
roles on the development of T1D and T2D and potential
effectiveness for clinical practice.Abbreviations
AGE: Advanced glycation end products; AKT: Protein kinase B; AP-1: Activating
protein 1; BB: BioBreeding diabetes-prone; BBR: BioBreeding diabetes-resistant;
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kappa beta kinase beta; IRAK: Interleukin-1 receptor-associated kinase;
IRF3: Interferon-regulatory factor 3; IRS-1: Insulin receptor 1 substrate; JNKs:
c-Jun N-terminal kinases; LPS: Lipopolysacharide; LRR: Leucine-rich repeat;
MAPK-p38: Mitogen-activated protein kinase p38; MD2: Myeloid differentiation
factor 2; MyD88: Myeloid differentiation factor 88; NFκB: Nuclear factor kappa B;
NOD: Nucleotide-binding oligomerization domain receptor; NLR: Nucleotide
binding oligomerization domain-like receptor (NLR) PAI-1, plasminogen
activator inhibitor-1; PKC: Protein kinase C; PRR: Pattern recognition receptors;
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SciELO: The Scientific Electronic Library Online SOCS3, suppressor of cytokine
signalling 3; T1D: Type 1 diabetes mellitus; T2D: Type 2 diabetes mellitus;
TAK1: Transforming growth factor β-activated kinase 1; TIR: Toll/interleukin-1
receptor; TIRAP: Intracellular Toll-interleukin 1 receptor domain-containing
adapter protein; TLRs: Toll-like receptors; TLR4: Toll-like receptor 4; TNF-α:
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